Specimen Collection Study Protocol

NCT04468386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2021-11-24

No results posted yet for this study

Summary

The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum. These reagents are for in vitro diagnostic use only.

Conditions

  • Focus in on Collecting Paired Specimens for Matrix Equivalency

Sponsors & Collaborators

  • Biomerica

    lead INDUSTRY

Principal Investigators

  • Elisabeth Laderman, Ph.D. · Biomerica, Inc.

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2021-05-30
Completion
2021-05-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04468386 on ClinicalTrials.gov